Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesLong-Term Debt RepaymentsNet Cash FlowOther Working Capital ChangesOther financing activitiesSales of Property, Plant and EquipmentShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Lifecore Biomedical, Inc. \De\ (LFCR) Short-Term Debt issuances (2016 - 2025)

Lifecore Biomedical, Inc. \De\ (LFCR) has 12 years of Short-Term Debt issuances data on record, last reported at -$6.0 million in Q1 2025.

  • For Q1 2025, Short-Term Debt issuances fell 297.69% year-over-year to -$6.0 million; the TTM value through Feb 2025 reached $129.3 million, up 120.81%, while the annual FY2024 figure was $149.6 million, 375.63% up from the prior year.
  • Short-Term Debt issuances reached -$6.0 million in Q1 2025 per LFCR's latest filing, up from -$13.1 million in the prior quarter.
  • Across five years, Short-Term Debt issuances topped out at $146.5 million in Q2 2024 and bottomed at -$32.0 million in Q1 2023.
  • Average Short-Term Debt issuances over 5 years is $17.4 million, with a median of $4.0 million recorded in 2022.
  • Peak YoY movement for Short-Term Debt issuances: skyrocketed 449.01% in 2023, then crashed 492.45% in 2024.
  • A 5-year view of Short-Term Debt issuances shows it stood at $18.0 million in 2021, then tumbled by 77.78% to $4.0 million in 2022, then crashed by 155.3% to -$2.2 million in 2023, then plummeted by 492.45% to -$13.1 million in 2024, then soared by 54.22% to -$6.0 million in 2025.
  • Per Business Quant database, its latest 3 readings for Short-Term Debt issuances were -$6.0 million in Q1 2025, -$13.1 million in Q4 2024, and $1.9 million in Q3 2024.